Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical immunotherapy: what's new.

Daniel N Sauder1, Mona Z Mofid

  • 1Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-0900, USA. dsauder@jhmi.edu

Dermatologic Clinics
|April 20, 2005
PubMed
Summary

Targeted therapies for skin diseases are advancing rapidly. New topical immune response modifiers, like Toll-like receptor agonists and calcineurin inhibitors, improve treatment for various skin conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A possible role for CD8+ T lymphocytes in the cell-mediated pathogenesis of pemphigus vulgaris.

Mediators of inflammation·2013
Same author

Novel use of polymethyl methacrylate (PMMA) microspheres in the treatment of infraorbital rhytids.

Journal of cosmetic dermatology·2013
Same author

A recombinant human hyaluronidase sustained release gel for the treatment of post-surgical edema.

International journal of dermatology·2013
Same author

Squamous cell carcinoma manifesting as cutaneous cystic lesions.

Cutis·2012
Same author

IL-12 and IL-23 in health and disease.

Expert review of clinical immunology·2010
Same author

Topical immunotherapy for skin disease.

Expert review of clinical immunology·2010

Area of Science:

  • Dermatology
  • Immunology
  • Molecular Biology

Background:

  • Molecular understanding of dermatologic disease pathogenesis is crucial for developing effective treatments.
  • Topical immune response modifiers have significantly advanced the management of cutaneous diseases.
  • The development of targeted therapies represents a major progress in dermatology.

Purpose of the Study:

  • To highlight the advancements in topical immune response modifiers for dermatologic conditions.
  • To discuss the role of Toll-like receptor agonists and calcineurin inhibitors in treating skin diseases.
  • To provide insights into the future of targeted immunotherapies in dermatology.

Main Methods:

  • Review of current literature on topical immune response modifiers.
  • Analysis of the mechanisms of action for Toll-like receptor agonists and calcineurin inhibitors.
  • Discussion of clinical applications and impact on dermatologic treatment.

Main Results:

  • Topical immune response modifiers, including Toll-like receptor agonists and calcineurin inhibitors, offer effective treatment options.
  • These agents enable clinicians to manage a broad spectrum of benign, premalignant, and malignant skin conditions.
  • The use of these targeted therapies enhances the understanding of disease processes.

Conclusions:

  • Topical immune response modifiers represent a significant therapeutic advancement in dermatology.
  • Future research will likely yield even more sophisticated targeted immunotherapies for skin diseases.
  • Continued exploration of molecular pathways will drive innovation in dermatologic treatment.

Related Experiment Videos